Merus N.V., a biotechnology company specializing in innovative oncology treatments, has announced the launch of a public offering of its common shares. All shares will be offered by Merus, with the company planning to provide underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The offering is contingent upon market and other conditions, and there is no assurance regarding the timing, size, or terms of completion. Merus is known for developing multispecific full-length antibodies and antibody-drug conjugates, including Biclonics®, Triclonics®, and ADClonics®.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。